Navigation Links
IRIDEX Introduces Non-Invasive MicroPulse™ Therapy for Glaucoma
Date:4/27/2012

MOUNTAIN VIEW, Calif., April 27, 2012 /PRNewswire/ -- IRIDEX Corporation today announced the launch of a new non-invasive, in-office glaucoma procedure based on its proprietary MicroPulse™ technology.  The new glaucoma therapy, a tissue-sparing, repeatable therapy called MicroPulse Laser Trabeculoplasty (MLT), was introduced by IRIDEX at the recent American Society of Cataract and Refractive Surgery (ASCRS).

Glaucoma is the leading cause of adult irreversible blindness. It is estimated that more than 4 million people in the US and approximately 60 million people worldwide are afflicted with the disease today.

MLT was first introduced by IRIDEX in its infrared laser platforms, but recent technology advancements have now made it available with the IRIDEX green laser system (IQ 532), our most versatile and highest selling laser used by the broadest group of ophthalmologists. The unique ability of the IQ 532 to offer tissue-sparing repeatable therapies for both glaucoma and retinal diseases represents a market breakthrough as well as providing ophthalmologists a very high return on their capital investment, said Dr. Dominik Beck, IRIDEX President and CEO.

David Gossage, M.D., medical director of the Gossage Eye Institute, noted that the addition of the MicroPulse module to the IQ 532 system makes it a valid option for a much broader patient population than has historically been the case.

"Compared to other lasers used for the treatment of glaucoma, the IQ 532 with the MicroPulse module offers greater versatility because it can also be used for a range of other conditions including diabetic macular edema, proliferative diabetic retinopathy, and retinal tears," Dr. Gossage said.  "I'm comfortable offering MLT to glaucoma patients as a first-line option because of its potential to reduce intraocular pressure without causing tissue damage."

MLT produces laser pulses at very short durations to create a therapeutic
'/>"/>

SOURCE IRIDEX Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. IRIDEX to Present at Upcoming Investment Conferences
2. IRIDEX Reports 2011 Fourth Quarter and Year-End Results
3. IRIDEX Announces Fourth Quarter and Full Year 2011 Conference Call and Release Date
4. IRIDEX MicroPulse™ Laser Therapy Enhances Visual Function in Patients with Central Serous Chorioretinopathy (CSC)
5. IRIDEX to Present at the Sidoti & Company New York Micro Cap Conference
6. Cutera and IRIDEX Announce Acquisition of IRIDEX Aesthetic Business Unit
7. 10-Year Study Demonstrates IRIDEX MicroPulse™ Laser Therapy Safe, Effective for Patients with Diabetic Macular Edema
8. IRIDEX Signs License and Distribution Agreement with Leader in Eye Care
9. IRIDEX Reports 2011 Third Quarter and Nine-Month Results
10. IRIDEX Announces Third Quarter 2011 Conference Call and Release Date
11. IRIDEX Launches New MicroPulse™ Module Targeting the Broad Ophthalmology Laser Photocoagulation Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... -- Research and Markets has announced the ... Film Industry Report 2014" report to their offering. ... Global And Chinese Medical X-Ray Film Industry Report 2014 ... state of the Global medical X-ray film industry with ... provides a basic overview of the industry including definitions, ...
(Date:7/11/2014)... Australia , July 11, 2014  Australian drug ... announced that it has raised A$19.3 million via a ... Europe , the U.S., Asia ... A$3 million from a share purchase plan (SPP) to ... million will be made in two tranches. ...
(Date:7/11/2014)... LOUIS , July 11, 2014 /PRNewswire/ ... device company, announced today the positive, cost-effective ... its innovative SPiNPerc™ procedure. The SPiNPerc endobronchial ... of a percutaneous approach to biopsy when ... Hospitals, patients and physicians experience positive financial ...
Breaking Medicine Technology:Global and Chinese Medical X-ray Film Industry Report 2014 2Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3Veran Medical Publishes Lung Cancer Patient Management Study 2
... Dec. 17 Novavax, Inc.,(Nasdaq: NVAX ) ... recombinant trivalent seasonal influenza virus-like particle (VLP),vaccine. The ... two,influenza vaccine programs that Novavax is developing using ... candidate is,currently in Phase I/IIa clinical trials., ...
... Product Developed Through Joint Venture Between Bristol-Myers Squibb and ... First of Its Kind in HIV Treatment -, ... The European Commission has granted marketing authorization for,ATRIPLA(R) (efavirenz ... ATRIPLA for commercialization in the,27 countries of the European ...
Cached Medicine Technology:Novavax Announces Preclinical Results for Seasonal Influenza Vaccine Program 2Novavax Announces Preclinical Results for Seasonal Influenza Vaccine Program 3European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 2European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 3European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 4European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 5European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 6European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 7European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 8European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 9
(Date:7/12/2014)... (PRWEB) July 12, 2014 The largest ... Centers, is pleased to announce that it will be ... This new facility will join four Atlanta-based Nova Medical ... located at 3209 Deans Bridge Road, and will be ... Friday. , “With Nova’s treatment philosophy of rapid ...
(Date:7/11/2014)... 12, 2014 Recently, DressyQuinceanera.com, a well-known ... Quinceanera Dama dresses to its online category. Furthermore, ... offered at deeply discounted rates, up to 62% off. ... are equally excellent in terms of quality and style. ... Similar discounts are also offered for the company’s other ...
(Date:7/11/2014)... Down reports that tickets to the Argentina vs. Germany ... between Brazil and Netherlands are in high demand. ... 12th at Estadio Nacional de Brasilia Mane Garrincha Brasila, Federal ... July 13th at Estadio Jornalista Mario Filho - Estadio do ... Cup are guaranteed to be authentic and are covered by ...
(Date:7/11/2014)... News) -- Reducing the number of deer in an ... and other tick-borne infections among people, new research indicates. ... manipulated to reduce human interactions with deer, infected nymphal ... researchers wrote. White-tailed deer are the primary host ... people. The study included nearly all the permanent ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 Volunteers from ... against drug abuse this week with drug education lectures, ... education booklet distribution in cities around the world. , ... U.S. National Institute on Drug Abuse, abuse of alcohol ... annually in crime, lost work, decreased productivity and healthcare. ...
Breaking Medicine News(10 mins):Health News:Nova Medical Centers To Open New Facility in Augusta, Georgia 2Health News:DressyQuinceanera.com: Beautiful Quinceanera Dama Dresses At Low Prices 2Health News:Argentina vs. Germany World Cup Finals Tickets & Brazil vs. Netherlands 3rd Place World Cup Tickets Are in Huge Demand 2Health News:Scientologists Taking Action against Drug Abuse 2Health News:Scientologists Taking Action against Drug Abuse 3
... with effects of prescription drugs for heart troubles, researcher says ... of Americans who are taking traditional herbal medications for heart ... new report says. , "They may be safe," said Dr. ... Arizona, and author of a report in the Feb. 9 ...
... ... ability to convert into a stylish, comfortable footrest , ... Las Vegas (PRWEB) February 1, 2010 -- ... Chair® Recliners and other wellness solutions, announced today the introduction of its new and ...
... androgen deprivation, official says , MONDAY, Feb. 1 ... the physicians who treat them are being warned ... the malignancy might increase the risk of heart ... substantial amount of data demonstrating that ADT adversely ...
... scored lowest on test also had worst outcomes, study reports, ... or thinking abilities could signal an increased likelihood for a ... men who were not diagnosed as having dementia but who ... greatly increased risk for stroke. , It,s not yet clear ...
... , Less serious recurrence seen with Ponseti casting method , ... in a thousand babies born in the United States , but ... feet compatible with an active, normal lifestyle. A new study in the ... Joint Surgery (JBJS) compared two common treatment options for clubfoot – ...
... , GREENWOOD VILLAGE, Colo. , Feb. ... revenue cycle solutions for the healthcare industry, announced today ... electronic EDI 278 transaction to UnitedHealthcare conforming to new ... UnitedHealthcare requests hospitals to submit EDI notification of each ...
Cached Medicine News:Health News:Herbal Remedies Can Cause Cardiac Problems 2Health News:Herbal Remedies Can Cause Cardiac Problems 3Health News:Human Touch Introduces New CirQlation™ Elite Foot & Calf Massager Providing Ultimate Targeted Relief for Tired Feet and Calves 2Health News:Human Touch Introduces New CirQlation™ Elite Foot & Calf Massager Providing Ultimate Targeted Relief for Tired Feet and Calves 3Health News:Human Touch Introduces New CirQlation™ Elite Foot & Calf Massager Providing Ultimate Targeted Relief for Tired Feet and Calves 4Health News:Experts Issue Warning on Prostate Hormone Therapy 2Health News:Experts Issue Warning on Prostate Hormone Therapy 3Health News:Poor Mental Functioning May Predict Stroke 2Health News:Poor Mental Functioning May Predict Stroke 3Health News:Study Finds Ponseti Method of Clubfoot Correction Leads to Lower Surgical Rates and Less Revision Surgery 2Health News:Study Finds Ponseti Method of Clubfoot Correction Leads to Lower Surgical Rates and Less Revision Surgery 3Health News:Study Finds Ponseti Method of Clubfoot Correction Leads to Lower Surgical Rates and Less Revision Surgery 4Health News:Recondo Technology Announces Omni278 UnitedHealthcare Admission Notification Service 2Health News:Recondo Technology Announces Omni278 UnitedHealthcare Admission Notification Service 3
... world-class clinician documentation and electronic medical record ... the specific needs of intensive care units ... deep clinical functionality has secured its place ... in critical care, and its the most ...
... EncounterPRO Electronic Health Record ... System (WfMS) Specialties that ... and Immunology, Cardiology, Dermatology, ... Medicine, Neurology, Neurosurgery, Obstetrics ...
... developed a touchscreen EHR and is scheduled ... user can choose to use a mouse, ... eye contact while recording encounter results. If ... also runs on a pen tablet that ...
Dairylands Health Information Management solutions provides healthcare organizations a suite of integrated applications for managing patient records, optimizing reimbursement and regulatory complianc...
Medicine Products: